Knights of Columbus Asset Advisors LLC Grows Stock Position in KALA BIO, Inc. (NASDAQ:KALA)

Knights of Columbus Asset Advisors LLC grew its position in shares of KALA BIO, Inc. (NASDAQ:KALA) by 100.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,834 shares of the company’s stock after purchasing an additional 2,417 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in KALA BIO were worth $34,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. UBS Group AG raised its stake in KALA BIO by 518.7% in the 1st quarter. UBS Group AG now owns 1,918 shares of the company’s stock valued at $29,000 after acquiring an additional 1,608 shares during the period. Bank of America Corp DE raised its position in shares of KALA BIO by 201.2% in the fourth quarter. Bank of America Corp DE now owns 13,284 shares of the company’s stock valued at $507,000 after purchasing an additional 8,874 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of KALA BIO in the second quarter valued at approximately $240,000. Geode Capital Management LLC purchased a new stake in shares of KALA BIO during the 2nd quarter valued at approximately $259,000. Finally, BlackRock Inc. boosted its holdings in KALA BIO by 36.1% in the 1st quarter. BlackRock Inc. now owns 21,382 shares of the company’s stock worth $322,000 after buying an additional 5,675 shares during the period. Institutional investors own 24.61% of the company’s stock.

Wall Street Analysts Forecast Growth

KALA has been the topic of a number of analyst reports. HC Wainwright lowered their target price on shares of KALA BIO from $22.00 to $21.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of KALA BIO in a research report on Monday, April 1st.

KALA BIO Stock Down 3.2 %

Shares of KALA opened at $6.59 on Monday. KALA BIO, Inc. has a twelve month low of $5.10 and a twelve month high of $19.35. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 5.10. The business’s 50-day moving average price is $7.44 and its 200-day moving average price is $7.21.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings data on Friday, March 29th. The company reported ($3.18) EPS for the quarter. On average, analysts predict that KALA BIO, Inc. will post -11.28 earnings per share for the current year.

KALA BIO Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery.